David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X:
“EV binds Nectin-4 at the cell surface, so where it’s expressed matters.
In Clinical Cancer Research, we discuss Klümper et al: a membranous Nectin-4 + NECTIN4 amp score sorts EV ORRs into 77% / 43% / 26%. Next test: EV+pembro.”
Title: Location, Location, Location: Membranous Nectin-4 as a Biomarker for Enfortumab Vedotin
Authors: James A. Rodrigues, Hikmat Al-Ahmadie, David H. Aggen, David B. Solit
You can also read:
Guru Sonpavde: NECTIN4 RNA May Help Predict Benefit From EV Plus Pembrolizumab